Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is characterized by a relapsing and remitting course. Appropriate assessment of disease activity is critical for adequate treatment decisions. In addition to endoscopic mucosal healing, histologic remission is emerging as a treatment target and a key factor in the evaluation of disease activity and therapeutic efficacy. However, there is no standardized definition of histologic remission, limiting the utility of histologic scoring, and manual pathologist evaluation is subject to intra-and inter-observer variability. Machine learning approaches are increasingly being developed to aid pathologists in accurate and reproducible scoring of histology, and can enable sensitive assessment of clinically relevant features. Here we report a proof-of-concept study using the PathAI platform to develop ML models for identification and quantification of UC histological features directly from hematoxylin and eosin (H&E)-stained whole slide images. Model-predicted histological features were used to quantify tissue area proportions and cell count proportions and densities, which correlated with disease severity and pathologist-assigned Nancy Histological Index (NHI) scores. Moreover, using multivariate analysis based on selected model-predicted histological features, we were able to accurately predict NHI scores, with a weighted kappa (k=0.93) and Spearman correlation (ρ=0.93, p<0.001) when compared to manual pathologist consensus NHI scores. We were also able to predict histological remission, based on the resolution of active inflammation, with high accuracy of 0.94. These results demonstrate the accuracy of ML models in quantifying histologic features of UC and predicting NHI scores, and highlight the potential of this approach to enable standardized and robust assessment of histologic remission for improved evaluation of disease activity and prognosis.
Competing Interest Statement
F.N., K.S., P.M., S.H., C.J., M.L., D.F., I.W., A.H.B., M.B.R., A.K., and M.G.D. are currently, or were formerly, employed at PathAI, Inc. S.K. is employed at PathAI Diagnostics.
Funding Statement
This work was funded by PathAI, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
WCG IRB has waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.